CN1269501C - 一种治疗慢性结肠炎的药物及制备方法 - Google Patents
一种治疗慢性结肠炎的药物及制备方法 Download PDFInfo
- Publication number
- CN1269501C CN1269501C CN 200410011206 CN200410011206A CN1269501C CN 1269501 C CN1269501 C CN 1269501C CN 200410011206 CN200410011206 CN 200410011206 CN 200410011206 A CN200410011206 A CN 200410011206A CN 1269501 C CN1269501 C CN 1269501C
- Authority
- CN
- China
- Prior art keywords
- colon
- group
- medicine
- peace
- thick paste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 79
- 229940079593 drug Drugs 0.000 title claims abstract description 41
- 206010009887 colitis Diseases 0.000 title claims abstract description 12
- 230000001684 chronic effect Effects 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title abstract description 8
- 230000008569 process Effects 0.000 title abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 230000006837 decompression Effects 0.000 claims abstract description 6
- 239000000706 filtrate Substances 0.000 claims abstract description 6
- 238000010992 reflux Methods 0.000 claims abstract description 6
- 239000009806 pulsatillae Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 abstract description 49
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 14
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 14
- 238000009825 accumulation Methods 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000002950 deficient Effects 0.000 abstract description 2
- 241000972673 Phellodendron amurense Species 0.000 abstract 4
- 241000132012 Atractylodes Species 0.000 abstract 2
- 241000202807 Glycyrrhiza Species 0.000 abstract 2
- 241000206469 Pulsatilla Species 0.000 abstract 2
- 238000001914 filtration Methods 0.000 abstract 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 abstract 2
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 description 120
- 241000700159 Rattus Species 0.000 description 52
- 210000002784 stomach Anatomy 0.000 description 37
- 241001465754 Metazoa Species 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 22
- 230000037396 body weight Effects 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 210000000936 intestine Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 206010012735 Diarrhoea Diseases 0.000 description 15
- 210000004877 mucosa Anatomy 0.000 description 14
- 206010030113 Oedema Diseases 0.000 description 13
- 240000008042 Zea mays Species 0.000 description 13
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 13
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 13
- 235000005822 corn Nutrition 0.000 description 13
- 238000003304 gavage Methods 0.000 description 13
- 239000006187 pill Substances 0.000 description 13
- 235000013305 food Nutrition 0.000 description 10
- 230000008595 infiltration Effects 0.000 description 10
- 238000001764 infiltration Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 208000025865 Ulcer Diseases 0.000 description 9
- 208000001848 dysentery Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 206010000087 Abdominal pain upper Diseases 0.000 description 8
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 238000005728 strengthening Methods 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 7
- 210000000436 anus Anatomy 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000000114 Pain Threshold Diseases 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 229940027941 immunoglobulin g Drugs 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 230000037040 pain threshold Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 102000003390 tumor necrosis factor Human genes 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000001142 anti-diarrhea Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001047 pyretic effect Effects 0.000 description 4
- 230000003014 reinforcing effect Effects 0.000 description 4
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 4
- 229960001940 sulfasalazine Drugs 0.000 description 4
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 206010028140 Mucous stools Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000000918 epididymis Anatomy 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 229940099472 immunoglobulin a Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 210000004915 pus Anatomy 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- NBSRUZQXRUNPNY-FOCLMDBBSA-N NS(=O)(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound NS(=O)(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O NBSRUZQXRUNPNY-FOCLMDBBSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010057071 Rectal tenesmus Diseases 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- WNYFTWLTSLCQLO-UHFFFAOYSA-N [As].N1=CC=CC=C1 Chemical compound [As].N1=CC=CC=C1 WNYFTWLTSLCQLO-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229950008351 salazosulfamide Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000012271 tenesmus Diseases 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000005622 photoelectricity Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 208000016303 spleen symptom Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 性别 | 给药前体重(g) | 给药后第7日体重(g) | 给药后第14日体重(g) |
对照组结肠安肠溶片结肠安肠溶片 | 雄性雌性灌胃雄性雌性灌肠雄性雌性 | 20.1±0.4520.1±0.4320.1±0.5520.1±0.4120.1±0.4920.1±0.43 | 25.0±1.0324.5±1.325.0±0.9924.6±1.0924.8±0.8724.3±1.06 | 29.3±1.5928.8±1.3629.1±1.1228.5±1.2928.5±1.5128.2±1.42 |
组别 | 给药前体重(g) | 给药后不同时间(周)大鼠体重(g) | ||||||
2周 | 4周 | 6周 | 8周 | 10周 | 12周 | 14周 | ||
对照组♂♀高剂量♂♀中剂量♂♀低剂量♂♀ | 71.8±5.171.3±5.171.1±4.771.3±5.471.3±5.071.5±5.771.2±4.971.2±5.9 | 126.7±14.6120.3±15.5123.5±12.2119.9±12.4127.9±13.7118.0±10.8129.3±10.9121.7±11.4 | 174.2±21.3159.6±22.9175.5±21.2158.4±17.7176.5±21.3161.5±17.6178.2±20.6163.5±19.2 | 220.1±24.4196.5±29.9222.3±25.5192.2±23.2220.4±25.7194.5±24.9224.3±25.0200.6±24.8 | 248.3±23.8220.7±26.3247.5±25.9216.6±25.4252.2±25.9218.2±27.1254.0±30.3224.0±25.7 | 272.0±26.4243.3±28.8270.0±26.5239.0±25.7274.9±25.9240.4±23.6278.0±35.3248.1±27.9 | 296.2±27.9260.0±27.7292.5±26.7258.0±24.6298.4±26.2259.3±27.0302.3±36.5265.8±28.1 | 310.2±29.7272.0±26.4307.8±26.1270.7±22.0311.0±28.1268.3±23.9316.4±29.4279.6±27.2 |
组别 | 给药后不同时间(周)大鼠体重(g) | 停药后3周体重 | |||||
16周 | 18周 | 20周 | 22周 | 24周 | 26周 | ||
对照组♂♀高剂量♂♀中剂量♂♀低剂量♂♀ | 323.2±31.7283.5±27.1321.8±29.5280.3±22.8325.1±28.8282.0±27.1330.0±31.2291.4±30.6 | 338.7±35.0294.4±28.2333.6±30.5289.8±23.4335.2±29.4292.8±27.9344.4±35.1303.2±30.1 | 352.0±38.4307.5±27.8348.8±35.3300.2±24.7350.4±33.3303.6±29.4360.2±38.3315.8±29.7 | 367.0±41.1318.2±30.7360.7±40.4313.1±27.1357.6±34.7314.6±28.1376.3±38.6327.0±30.0 | 383.5±45.4327.8±35.2376.2±46.7322.0±32.1381.7±37.0325.4±31.7391.0±41.7336.8±37.4 | 400.8±46.6338.2±38.5394.4±48.4331.3±36.1398.3±41.5336.5±31.7410.0±44.3348.0±36.8 | 413.4±44.6350.1±32.4406.3±37.9344.1±40.4408.3±32.8348.4±31.2424.2±38.0360.0±32.4 |
组别 | 动物数(只) | 给药后不同时间(周)大鼠摄食(g)饮水量(ml) | 动物数(只) | ||||||
二周 | 四周 | 六周 | 八周 | 十周 | 十二周 | 十四周 | |||
对照组♂水食♀水食 | 2020 | 444.6±21.3248.3±14.5410.0±29.0244.0±10.1 | 516.3±65.0288.3±17.5485.0±20.5272.0±12.1 | 579.0±43.2331.6±7.6524.0±42.1310.3±8.3 | 616.6±67.9372.6±14.1549.6±27.0344.6±5.5 | 730.0±22.9414.3±6.0674.6±36.4379.3±7.5 | 832.3±36.4465.6±12.8770.0±30.7415.0±8.8 | (15)(15) | 630.0±18.0353.3±12.5521.6±23.0314.3±14.6 |
高剂量♂水食♀水食 | 2020 | 432.3±19.7244.6±15.0395.3±25.0242.0±13.7 | 504.3±23.5282.3±17.0474.6±11.7265.0±11.7 | 587.3±53.5326.6±11.7506.6±19.4294.3±9.2 | 591.6±50.8366.6±12.5558.0±35.3335.0±8.6 | 724.3±38.1407.6±11.2660.3±39.5372.0±13.1 | 815.3±23.4457.3±16.6753.6±37.6409.3±13.0 | (15)(15) | 610.6±16.2345.6±8.1512.3±14.0307.0±12.1 |
中剂量♂水食♀水食 | 2020 | 420.6±13.2250.0±10.0383.3±26.4240.0±10.0 | 510.0±21.0290.0±10.0497.6±36.5270.0±18.0 | 580.6±31.6323.3±6.1514.6±41.0308.3±7.6 | 600.0±65.0378.0±9.1558.0±35.3340.0±5.0 | 736.6±42.1410.3±9.6680.6±42.0375.3±14.1 | 822.6±33.1460.6±12.8760.0±36.0412.3±11.2 | (15)(15) | 620.3±33.3356.6±8.5533.3±26.3317.0±8.5 |
低剂量♂水食♀水食 | 2020 | 426.6±15.2255.6±7.3418.0±19.4243.3±12.5 | 498.0±19.9292.6±15.3470.3±31.0275.0±13.2 | 590.6±39.1336.6±7.6510.6±36.3316.6±5.7 | 606.3±25.0382.3±6.8539.0±42.2350.0±13.2 | 717.0±25.1421.6±7.6667.6±30.2388.6±13.3 | 840.3±25.5475.0±4.3780.0±26.0421.6±7.6 | (15)(15) | 614.6±14.1361.6±12.5517.3±19.6321.6±7.6 |
给药后不同时间(周)大鼠摄食(g)饮水量(m.) | ||||||||||
十六周 | 十八周 | 二十周 | 动物数(只) | 二十二周 | 动物数(只) | 二十四周 | 动物数(只) | 二十六周 | 动物数(只) | 停药后三周 |
677.3±46.4388.3±7.6545.0±30.0338.3±36.1656.6±39.0376.3±5.1521.0±26.5323.3±6.1660.0±47.2381.6±6.5538.3±36.1335.3±11.0648.6±39.2395.3±13.7530.0±18.0345.3±9.0 | 632.3±46.5405.0±15.0505.0±45.8350.6±11.0622.3±35.1390.0±17.4495.0±35.5344.0±7.9642.6±26.2406.6±13.3500.3±17.8344.6±11.5615.3±22.4414.3±15.6514.3±14.0357.3±5.8 | 702.3±22.5420.0±15.1552.0±24.2360.0±10.0687.3±31.6413.0±10.1534.6±39.0351.6±12.5699.0±16.5416.6±12.5546.6±20.8355.3±9.8717.3±32.8428.6±10.2560.6±20.5368.3±7.6 | (14) | 726.0±22.5430.6±6.0535.0±35.0368.3±12.5719.3±23.7420.3±5.5477.6±30.5332.6±12.8704.6±20.0426.6±10.1518.3±34.0361.6±16.0696.3±26.5439.0±4.5528.6±17.9378.6±10.4 | (14) | 602.0±46.3442.3±11.6480.6±35.2378.6±12.6590.0±35.5430.6±10.0436.0±28.5343.3±17.5852.6±43.8435.6±9.2488.0±33.7374.3±12.8556.1±52.9423.3±12.5475.6±25.0389.0±8.5 | (14) | 684.0±35.7450.0±14.2579.6±25.4380.0±10.0628.0±35.6410.0±13.2525.0±27.8347.0±13.7659.0±31.1444.0±6.9559.6±16.5378.3±15.2622.0±40.0431.0±13.4568.3±22.5391.6±7.6 | (10)(10)(9)(9)(10)(10)(9)(10) | 439.6±19.5292.6±24.1361.6±40.7257.6±7.0368.0±21.2253.3±7.6315.0±30.4227.0±13.1428.0±24.9285.0±13.2356.3±29.9250.6±9.0413.6±33.6284.0±10.1351.3±44.0264.6±14.5 |
时间 | 组别(g/kg) | 心(g/100g) | 肝(g/100g) | 脾(g/100g) | 肺(g/100g) | 肾(g/100g) | 肾上腺(mg/100g) | 甲状腺(mg/100g) |
给药后13周 | 对照组高剂量组中剂量组低剂量组 | 0.32±0.020.34±0.040.32±0.050.33±0.03 | 3.5±0.43.3±0.53.4±0.63.5±0.6 | 0.40±0.050.41±0.060.45±0.070.43±0.10 | 0.75±0.10.79±0.10.75±0.10.76±0.2 | 0.33±0.040.34±0.040.33±0.030.34±0.03 | 15.4±2.216.0±3.314.8±3.215.0±2.2 | 14.0±1.814.6±1.913.0±2.115.0±2.3 |
给药后26周 | 对照组高剂量组中剂量组低剂量组 | 0.31±0.060.33±0.040.30±0.030.31±0.04 | 3.3±0.43.1±0.33.0±0.53.2±0.4 | 0.39±0.070.40±0.050.44±0.100.42±0.08 | 0.70±0.20.72±0.10.70±0.10.71±0.1 | 0.31±0.050.32±0.060.31±0.070.32±0.05 | 14.1±2.915.1±2.714.0±2.514.2±2.3 | 13.5±3.414.0±3.213.6±2.914.0±2.2 |
停药后3周 | 对照组高剂量组中剂量组低剂量组 | 0.30±0.020.31±0.040.30±0.040.29±0.03 | 3.2±0.63.2±0.53.1±0.33.2±0.4 | 0.39±0.090.40±0.110.44±0.080.42±0.07 | 0.68±0.10.68±0.090.66±0.10.69±0.1 | 0.30±0.040.31±0.050.30±0.030.31±0.06 | 13.7±3.214.0±2.413.5±2.113.8±2.4 | 12.9±1.513.0±2.012.7±1.213.2±2.3 |
时间 | 组别(g/kg) | 睾丸(g/100g) | 附睾(g/100g) | 子宫(g/100g) | 卵巢(mg/100g) | 前列腺(g/100g) | 胸腺(g/100g) | 脑(g/100g) |
给药后13周 | 对照组高剂量组中剂量组低剂量组 | 0.56±0.030.54±0.070.54±0.020.57±0.10 | 0.21±0.030.19±0.010.20±0.070.22±0.03 | 0.20±0.050.19±0.050.20±0.080.21±0.05 | 51.4±15.950.9±12.152.2±14.053.5±11.9 | 0.14±0.050.13±0.020.14±0.030.15±0.03 | 0.15±0.040.16±0.050.15±0.030.15±0.05 | 0.58±0.070.60±0.060.58±0.070.56±0.08 |
给药后26周 | 对照组高剂量组中剂量组低剂量组 | 0.55±0.100.52±0.060.53±0.100.54±0.07 | 0.20±0.050.18±0.030.19±0.050.20±0.03 | 0.19±0.050.18±0.040.20±0.070.20±0.05 | 49.9±14.648.6±12.850.7±10.051.5±14.1 | 0.13±0.050.12±0.030.14±0.020.14±0.03 | 0.14±0.030.15±0.030.14±0.040.14±0.03 | 0.54±0.070.56±0.060.53±0.070.52±0.06 |
停药后3周 | 对照组高剂量组中剂量组低剂量组 | 0.53±0.090.50±0.060.52±0.080.50±0.05 | 0.17±0.030.16±0.020.18±0.020.17±0.02 | 0.18±0.060.19±0.050.17±0.030.18±0.03 | 46.2±7.046.6±8.047.4±8.648.8±6.6 | 0.13±0.020.12±0.040.13±0.020.13±0.02 | 0.13±0.030.14±0.020.13±0.020.13±0.03 | 0.50±0.060.51±0.070.52±0.050.50±0.07 |
时间 | 组别 | 动物数(只) | ALT(U/L) | TP(g/L) | ALB(g/L) | ALP(U/L) | AST(U/L) |
给药后13周 | 对照组高剂量组中剂量组低剂量组 | 10101010 | 53.3±9.250.4±9.353.6±8.752.0±8.3 | 64.6±2.365.1±2.464.9±2.465.0±2.8 | 30.6±2.831.5±3.331.0±2.430.3±2.7 | 224.1±36.9237.2±47.3224.8±40.2228.7±44.7 | 230.1±32.5233.7±31.8226.3±47.1230.5±37.1 |
给药后26周 | 对照组高剂量组中剂量组低剂量组 | 10101010 | 53.5±6.851.8±7.853.8±6.154.2±6.7 | 64.9±1.964.2±2.263.9±2.165.9±2.8 | 30.8±3.030.7±2.630.4±2.531.1±2.8 | 222.5±46.9218.3±41.2219.3±39.7225.3±43.0 | 220.7±43.4214.6±46.5215.8±37.0216.3±39.2 |
停药后3周 | 对照组高剂量组中剂量组低剂量组 | 10101010 | 52.6±9.053.0±6.553.1±6.450.1±8.2 | 64.2±1.764.5±2.065.2±2.164.5±2.2 | 31.1±2.230.7±2.630.5±2.134.5±2.0 | 224.5±36.5220.8±36.8224.4±37.6215.9±38.4 | 223.0±32.8226.6±27.8219.3±38.5220.2±43.0 |
时间 | 组别 | 动物数(只) | UREA(mmol/L) | CR(μmol/L) | CHOL(mmol/L) | GLU(mmol/L) | T-BiL(μmol/L) |
给药后13周 | 对照组高剂量组中剂量组低剂量组 | 10101010 | 6.8±0.96.9±0.96.8±1.26.7±1.1 | 53.8±5.853.3±6.352.8±7.453.0±8.5 | 2.0±0.32.1±0.32.0±0.22.0±0.2 | 5.6±0.75.5±0.95.5±0.95.4±0.9 | 7.1±0.67.0±0.76.9±0.87.0±1.0 |
给药后26周 | 对照组高剂量组中剂量组低剂量组 | 10101010 | 7.0±1.06.9±1.07.0±0.97.1±0.7 | 55.0±6.354.0±8.453.2±7.856.0±7.7 | 2.0±0.32.1±0.22.1±0.32.0±0.3 | 5.6±0.85.5±0.75.6±0.75.5±0.7 | 7.3±0.67.0±0.87.3±0.97.0±0.8 |
停药后3周 | 对照组高剂量组中剂量组低剂量组 | 10101010 | 7.0±1.07.1±0.96.9±1.27.1±0.9 | 51.9±7.053.0±7.354.6±7.952.4±9.1 | 2.0±0.22.1±0.22.1±0.32.1±0.3 | 5.8±0.75.7±0.65.7±0.85.8±0.9 | 7.0±0.86.9±0.97.0±1.27.0±0.8 |
时间 | 组别 | 动物数(只) | WBC(×109/L) | LY(%) | MO(%) | GR(%) | RBC(×1012/L) | Hgb(g/L) | Pit(×109/L) | MCV(fL) | MCH(Pg) |
给药后13周 | 对照组高剂量组中剂量组低剂量组 | 10101010 | 9.2±3.29.6±3.39.3±2.89.4±3.7 | 77.0±6.778.0±5.476.7±4.776.6±5.5 | 7.8±1.17.2±1.27.3±1.47.4±1.2 | 14.0±4.815.3±5.814.8±4.816.1±6.3 | 7.0±0.57.3±0.37.1±0.47.2±0.4 | 133.9±10.3136.2±8.2138.2±7.8135.2±13.0 | 636.3±162.0681.2±137.0689.8±113.7703.0±143.5 | 54.6±1.654.9±2.055.0±1.155.0±1.2 | 19.2±0.419.0±0.219.1±0.419.1±0.4 |
给药后26周 | 对照组高剂量组中剂量组低剂量组 | 10101010 | 11.1±3.611.5±3.611.4±3.811.0±3.1 | 76.1±6.175.6±6.774.5±6.176.0±5.7 | 8.0±1.27.7±1.07.3±1.47.5±1.7 | 15.0±7.516.0±6.218.2±6.916.9±6.1 | 7.1±0.47.1±0.26.9±0.37.1±0.4 | 136.7±7.4135.7±7.7135.0±6.7136.3±7.6 | 685.7±123.5694.1±151.6673.7±131.1696.4±144.5 | 55.7±1.654.0±2.455.6±1.555.5±1.4 | 19.4±0.419.2±0.519.3±0.519.4±0.5 |
停药后3周 | 对照组高剂量组中剂量组低剂量组 | 10101010 | 11.0±4.811.8±5.211.2±5.012.0±5.4 | 76.6±7.375.1±7.076.2±7.475.4±8.2 | 7.2±1.57.3±1.77.6±1.27.5±1.4 | 16.6±8.017.5±8.216.8±7.317.6±8.9 | 7.0±0.57.1±0.47.0±0.47.1±0.5 | 144.5±7.0136.9±8.6138.7±7.2137.1±8.5 | 697.5±150.0712.0±147.7680.8±158.7700.6±156.2 | 55.7±1.055.3±1.755.4±2.055.7±1.5 | 19.9±1.019.7±0.419.8±0.419.5±0.5 |
组别(g/kg) | 动物数(只) | 体重(g) | |||
开始 | 给醋酸前 | 结束 | 前后差值 | ||
正常对照组 | 10 | 207.1±14.2 | 215.6±14.8* | 226.6±12.7* | 19.5±6.8* |
模型组 | 10 | 208.2±13.5 | 194.5±10.8 | 210.7±19.1 | 1.8±19.4 |
补脾益肠丸1.62 | 10 | 207.8±13.9 | 194.4±12.0 | 225.5±14.2 | 17.7±4.6* |
结肠安肠溶片3.12 | 10 | 207.1±11.4 | 193.7±13.3 | 228.2±15.1* | 19.1±6.9* |
结肠安肠溶片1.56 | 10 | 207.6±11.1 | 194.8±14.1 | 227.0±12.6* | 17.2±6.8* |
结肠安肠溶片0.78 | 10 | 207.5±11.6 | 195.5±12.6 | 226.6±15.8 | 15.7±8.7 |
组别(g/kg) | 动物数(只) | 水肿面积(cm2) | 充血积分 | 糜烂面积(cm2) | 总评分 |
正常对照组 | 10 | 0*** | 0.1±0.32*** | 0*** | 0.1±0.32*** |
模型组 | 10 | 2.15±0.57 | 2.6±0.51 | 0.38±0.10 | 4.9±0.32 |
补脾益肠丸1.62 | 10 | 1.20±0.76** | 1.0±0.47*** | 0.17±0.12*** | 3.8±1.13* |
结肠安肠溶片3.12 | 10 | 1.18±0.36*** | 0.9±0.56*** | 0.16±0.13*** | 3.7±1.16** |
结肠安肠溶片1.56 | 10 | 1.13±0.62** | 1.0±0.47*** | 0.18±0.10*** | 4.0±0.81** |
结肠安肠溶片0.78 | 10 | 1.40±0.39** | 1.3±0.48*** | 0.24±0.13* | 4.2±0.79* |
组别(g/kg) | 动物数(只) | TNF(ng/ml) | IL-2(ng/ml) | IgG(μg/ml) | IgA(μg/ml) |
正常对照组 | 10 | 0.86±0.23** | 2.41±0.71** | 1.62±0.41* | 0.12±0.02 |
模型组 | 10 | 1.15±0.16 | 1.44±0.31 | 1.95±0.22 | 0.14±0.03 |
补脾益肠丸1.62 | 10 | 0.91±0.22* | 2.05±0.38** | 1.56±0.39* | 0.11±0.05 |
结肠安肠溶片3.12 | 10 | 0.61±0.19*** | 2.18±0.61** | 1.63±0.22** | 0.11±0.02* |
结肠安肠溶片1.56 | 10 | 0.79±0.21** | 1.93±0.32** | 1.65±0.36* | 0.12±0.06 |
结肠安肠溶片0.78 | 10 | 0.92±0.13** | 1.79±0.39* | 1.84±0.32 | 0.13±0.03 |
组别(g/kg) | 动物数(只) | 体重(g) | 动物数(只) | 体重(g) | ||||
造型前 | 造型后 | 前后差值 | 给药前 | 给药后 | 前后差值 | |||
正常对照组 | 10 | ♀145.6±7.6 | 235.4±17.1** | 89.8±13.6*** | 10 | ♀236.4±17.7 | 292.8±23.5** | 56.4±15.9* |
♂143.8±8.6 | 254.6±18.3* | 110.8±15.7** | ♂255.2±19.5 | 330.0±20.9* | 74.8±5.9* | |||
模型组 | 70 | ♀143.2±8.6 | 209.3±18.8 | 66.1±16.6 | 10 | ♀212.4±12.4 | 249.0±17.2 | 36.6±6.2 |
♂144.0±11.2 | 223.5±31.67 | 79.5±27.5 | ♂234.6±29.2 | 277.6±50.2 | 43.0±25.0 | |||
柳氮磺吡啶片0.86 | 9 | ♀210.6±12.2 | 247.7±24.8 | 41.0±18.2 | ||||
♂234.8±19.5 | 305.0±38.6 | 70.2±24.6 | ||||||
固本益肠片1.64 | 10 | ♀209.6±8.0 | 251.6±15.3 | 42.0±9.4 | ||||
♂236.8±45.7 | 294.8±64.1 | 58.0±22.8 | ||||||
结肠安肠溶片3.12 | 10 | ♀212.2±8.4 | 267.8±21.6 | 55.6±15.1* | ||||
♂235.2±34.6 | 311.8±48.9 | 76.6±16.1* | ||||||
结肠安肠溶片1.56 | 10 | ♀212.4±15.9 | 259.4±17.9 | 47.0±20.4 | ||||
♂235.0±19.6 | 308.0±24.9 | 73.0±12.4* | ||||||
结肠安肠溶片0.78 | 10 | ♀210.6±17.3 | 253.6±15.1 | 43.0±5.5 | ||||
♂235.8±16.6 | 296.8±17.6 | 61.0±11.8 |
组别(g/kg) | 动物数(只) | 水肿面积(cm2) | 充血积分 | 糜烂面积(cm2) | 总评分 |
正常对照组 | 10 | 0*** | 0.1±0.32*** | 0*** | 0.1±0.32*** |
模型组 | 10 | 4.33±1.90 | 2.3±0.48 | 0.67±0.25 | 4.6±0.52 |
柳氮磺胺砒啶0.86 | 9 | 2.62±1.39* | 0.3±0.50*** | 0.43±0.05** | 3.3±0.50*** |
固本益肠片1.64 | 10 | 2.17±0.95** | 0.2±0.42*** | 0.46±0.09* | 3.2±0.42*** |
结肠安肠溶片3.12 | 10 | 1.30±0.96*** | 0.1±0.32*** | 0.26±0.12*** | 2.2±0.92** |
结肠安肠溶片1.56 | 10 | 1.67±0.55*** | 0.4±0.70*** | 0.39±0.14** | 3.2±0.79*** |
结肠安肠溶片0.78 | 10 | 1.82±0.87** | 0.7±0.82*** | 0.41±0.17* | 3.4±1.26* |
组别(g/kg) | 动物数(只) | NO(μmol/mgProt) | MDA(nmol/mgProt) | SOD(U/mgProt) | NO(μmol/L) | MDA(nmol/L) | SOD(U/L) |
正常对照组 | 10 | 1.16±0.47*** | 3.71±1.29*** | 130.8±10.3*** | 5.34±1.73*** | 4.25±0.99 | 202.0±8.75** |
模型组 | 10 | 3.33±1.13 | 6.97±1.53 | 65.9±24.3 | 12.46±4.85 | 8.21±2.16 | 187.9±10.28 |
柳氮磺胺砒啶0.86 | 9 | 2.24±0.58* | 5.05±1.49* | 94.6±25.7* | 7.39±4.51* | 5.68±1.43** | 204.2±6.39*** |
固本益肠片1.64 | 10 | 1.95±1.08* | 5.17±1.06** | 97.1±19.9** | 7.39±3.19* | 3.59±1.45*** | 226.6±13.7*** |
结肠安肠溶片3.12 | 10 | 1.72±0.57*** | 4.18±1.01*** | 113.5±20.5*** | 6.44±3.81** | 3.81±0.99*** | 203.2±8.91** |
结肠安肠溶片1.56 | 10 | 1.92±0.72** | 5.06±1.18** | 100.7±25.0** | 7.74±3.65* | 3.25±1.43** | 197.7±8.35* |
结肠安肠溶片0.78 | 10 | 2.11±0.72* | 5.65±0.86* | 93.8±29.3* |
组别 | 动物数(只) | 给药途径 | 分组痛阈值(秒) | 给药不同时间痛阈值(秒) | |||
1 | 2 | 3 | 4 | ||||
正常对照 | 10 | 灌胃灌肠交替 | 15.6±3.53 | 16.5±3.41 | 17.2±3.12 | 16.5±2.79 | 17.8±3.55 |
补脾益肠丸2.34 | 10 | 灌胃 | 15.4±3.95 | 26.0±4.76### | 31.4±7.58### | 28.8±5.75### | 27.0±7.54## |
结肠安肠溶片4.68 | 10 | 灌胃 | 15.5±4.35 | 28.9±9.94## | 35.1±6.67### | 29.9±9.41### | 31.0±8.61### |
结肠安肠溶片2.34 | 10 | 灌胃 | 15.5±3.68 | 32.0±8.97### | 29.8±8.20### | 29.4±9.23### | 24.6±8.43# |
结肠安肠溶片2.34 | 10 | 灌肠 | 15.6±4.03 | 34.3±7.83### | 31.4±4.99### | 29.2±7.51### | 24.4±6.62# |
结肠安肠溶片1.17 | 10 | 灌肠 | 15.6±3.92 | 26.7±9.12## | 29.4±5.66### | 22.8±7.17# | 22.2±6.76 |
组别(g/kg) | 动物数(只) | 给药途径 | 15分钟内扭体次数(次) | P |
正常对照—补脾益肠丸2.34结肠安肠溶片4.68结肠安肠溶片2.34结肠安肠溶片2.34结肠安肠溶片1.17 | 101010101010 | 灌胃灌肠交替灌胃灌胃灌胃灌肠灌肠 | 20.7±7.213.6±4.211.8±5.012.5±5.512.9±4.2513.9±5.3 | <0.05<0.01<0.05<0.05<0.05 |
组别(g/kg) | 动物数(只) | 给药途径 | 耳肿胀程度(mg) | P |
正常对照—补脾益肠丸2.34结肠安肠溶片4.68结肠安肠溶片2.34结肠安肠溶片2.34结肠安肠溶片1.17 | 1010101010 | 灌胃灌肠交替灌胃灌胃灌胃灌肠灌肠 | 9.3±2.266.4±2.595.9±2.424.8±2.594.6±1.9413.9±5.3 | <0.05<0.01<0.001<0.001>0.05 |
组别(g/kg) | 动物数(只) | 给药途径 | 伊文氏兰含量(μg/ml) | P |
正常对照—补脾益肠丸2.34结肠安肠溶片4.68结肠安肠溶片2.34结肠安肠溶片2.34结肠安肠溶片1.17 | 1010101010 | 灌胃灌肠交替灌胃灌胃灌胃灌肠灌肠 | 3.5±0.543.0±0.512.5±0.882.8±0.552.74±0.732.9±0.75 | <0.05<0.01<0.05<0.05>0.05 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410011206 CN1269501C (zh) | 2004-11-08 | 2004-11-08 | 一种治疗慢性结肠炎的药物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410011206 CN1269501C (zh) | 2004-11-08 | 2004-11-08 | 一种治疗慢性结肠炎的药物及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1631413A CN1631413A (zh) | 2005-06-29 |
CN1269501C true CN1269501C (zh) | 2006-08-16 |
Family
ID=34845585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410011206 Expired - Fee Related CN1269501C (zh) | 2004-11-08 | 2004-11-08 | 一种治疗慢性结肠炎的药物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1269501C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103690715B (zh) * | 2013-12-31 | 2015-11-18 | 刘雁 | 一种治疗缺血性结肠炎的中药 |
CN105232662A (zh) * | 2015-11-18 | 2016-01-13 | 吴斌 | 一种用于治疗慢性结肠炎的药物 |
CN111759978B (zh) * | 2020-07-06 | 2021-10-22 | 河北省中医院 | 一种治疗溃疡性结肠炎和湿疹的中药组合物及其制备方法和应用 |
CN113876860A (zh) * | 2021-11-26 | 2022-01-04 | 滨州医学院附属医院 | 一种治疗溃疡性结肠炎的药物组合物 |
-
2004
- 2004-11-08 CN CN 200410011206 patent/CN1269501C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1631413A (zh) | 2005-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103734548A (zh) | 用于治疗猪消化不良的饲料及其制备方法 | |
CN104258139A (zh) | 一种用于防治慢性型猪瘟疫的药物组合物及其制备方法 | |
CN104147536B (zh) | 一种治疗痔疮的药物组合物及其制备方法 | |
CN105028995A (zh) | 一种配合狗粮及其制备方法 | |
CN104524106A (zh) | 一种治疗前列腺炎、前列腺肥大的中药制剂及其制备方法 | |
CN1269501C (zh) | 一种治疗慢性结肠炎的药物及制备方法 | |
CN106668185A (zh) | 预防和治疗牛羊尿结石症的药物组合物 | |
CN103705796A (zh) | 一种治疗腹泻的药物组合物及其制备方法 | |
CN105214010A (zh) | 一种治疗慢性胆囊炎的中药制剂 | |
CN104905063A (zh) | 一种牛配合饲料及其制备方法 | |
CN104547186A (zh) | 用于预防、治疗禽霍乱的复方发酵型中药及其制备方法 | |
CN103933538A (zh) | 用于治疗脾肾阳虚型肝硬化腹水的药物及其制备方法 | |
CN104547902A (zh) | 中药制剂用于制备治疗慢性肠炎、阑尾炎药物中的用途 | |
CN104189413A (zh) | 用于治疗乌龟肠胃炎病的药物组合物及其制备方法 | |
CN100342888C (zh) | 一种治疗前列腺增生的中药制剂及其制备方法和应用 | |
CN1234407C (zh) | 一种治疗慢性前列腺炎的药物及其制备方法 | |
CN1256117C (zh) | 一种治疗慢性非特异性溃疡性结肠炎的药物及制备方法 | |
CN104645144A (zh) | 一种治疗肾炎的中药制剂及其制备方法 | |
CN1241596C (zh) | 治疗膀胱炎的口服中药制剂 | |
CN107296914A (zh) | 一种治疗高血压的中药组合物及其制备方法 | |
CN1217688C (zh) | 一种治疗慢性胃炎的药物及其制备方法 | |
CN104688952A (zh) | 一种治疗膀胱湿热型膀胱癌的中药组合物及其制备方法 | |
CN104491312A (zh) | 中药制剂在制备治疗前列腺炎、前列腺肥大药物中的用途 | |
CN103705820B (zh) | 用于治疗仔猪黄痢的药物及其制备方法 | |
CN104940777A (zh) | 一种治疗肝旺脾弱型经行泄泻的冲剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Changchun yinnuo Pharmaceutical Co.,Ltd. Assignor: Liu Xiaofeng Contract record no.: 2010220000029 Denomination of invention: Medicine for treating chronic colitis and its preparing process Granted publication date: 20060816 License type: Exclusive License Open date: 20050629 Record date: 20100623 |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Changchun yinnuo Pharmaceutical Co.,Ltd. Assignor: Liu Xiaofeng Contract record no.: 2010220000029 Date of cancellation: 20120110 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Jilin yinnuoke Pharmaceutical Co.,Ltd. Assignor: Liu Xiaofeng Contract record no.: 2012220000001 Denomination of invention: Medicine for treating chronic colitis and its preparing process Granted publication date: 20060816 License type: Exclusive License Open date: 20050629 Record date: 20120118 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20190123 Address after: 130500 Qunying Road 888, Jiutai Economic Development Zone, Changchun, Jilin Province Patentee after: Changchun yinnuo Pharmaceutical Co.,Ltd. Address before: 130031 No. 23 Convention and Exhibition Street, Jingkai District, Changchun City, Jilin Province Patentee before: Liu Xiaofeng |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210202 Address after: No. 999, Xingfu East Road, Zhenlai Economic Development Zone, Baicheng City, Jilin Province 137000 Patentee after: Jilin yinnuoke Pharmaceutical Co.,Ltd. Address before: 130500 Qunying Road 888, Jiutai Economic Development Zone, Changchun, Jilin Province Patentee before: Changchun yinnuo Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060816 Termination date: 20211108 |